Anixa Biosciences, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ANIX, updated each market day.
ANIX AI Sentiment
AI sees no strong directional signal for Anixa Biosciences, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Anixa Biosciences, Inc.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Sector
Exchange
Market Cap
$91,866,330
Cap Tier
Employees
4
Headquarters
SAN JOSE, CA
Listed Since
Oct. 7, 1983
Website
ANIX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANIX Volatility
Anixa Biosciences, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
